Publications by authors named "Mariantonietta Piccoli"
Drug utilization and medication adherence for the treatment of psoriatic arthritis: an Italian study.
Glob Reg Health Technol Assess
October 2024
Article Synopsis
- The study evaluates the use of biologic and targeted synthetic drugs for treating psoriatic arthritis (PsA) in Italy, specifically focusing on the role of biosimilar drugs.
- Conducted over four years at eight hospital pharmacies, the research tracked patients new to treatment, assessing their persistence and adherence to medication using the proportion of days covered (PDC).
- Findings revealed that patients on biosimilars showed better adherence and persistence than those on originators, and utilizing biosimilars resulted in significant cost savings, highlighting their potential benefits in healthcare resource optimization.
Article Synopsis
- This study looks at how often and consistently patients with psoriasis use different drugs over 1 to 5 years, specifically focusing on medications like Adalimumab and others.
- Researchers used real-life data to measure how well patients adhered to their treatment plans using the Proportion of Days Covered (PDC) method.
- While adherence to treatment was generally good, the study found that persistence (the duration patients stay on treatment) dropped significantly after the second year, highlighting the need for better strategies to encourage long-term treatment.
Article Synopsis
- The study aimed to evaluate adherence, persistence, and costs associated with biologic disease-modifying antirheumatic drugs (bDMARDs) in patients with Rheumatoid Arthritis across nine Italian hospital pharmacies.
- Researchers analyzed several bDMARDs, comparing the actual medication taken by patients (Received Daily Dose) to what was prescribed (Prescribed Daily Dose) to measure adherence and the length of time patients continued with each drug (persistence).
- Results indicated that adherence was generally high (over 0.8) for all drugs, but patients had difficulty maintaining treatment over longer periods, with median persistence ranging between 1.3 and 1.8 years.